(thirdQuint)Bioequivalence Study of Carvedilol Tablets USP 12.

5 mg Under Fasting Condition.

 Objective of this pivotal study was to assess the bioequivalence between Test Product: Carvedilol Tablets USP 12.

5 mg of M/s Ipca Laboratories Limited, India and the corresponding Reference Product: Coreg(R) (Carvedilol Tablets) 12.

5 mg Tablets of M/s GlaxoSmithKline, under fasting condition in normal, healthy, adult, human subjects in a randomized crossover study.

 The study was conducted with 42 healthy adult subjects.

 In each study period, a single 12.

5 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position.

 The duration of the clinical phase was approximately 11 days including washout period of at least 7 days between administrations of study drug in each study period.

.

 Bioequivalence Study of Carvedilol Tablets USP 12.

5 mg Under Fasting Condition@highlight

This is a randomized, open Label, balanced, two-treatment, two-period, two-sequence, single dose, cross over pivotal study.

 The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fasting condition in normal, healthy, adult, human subjects.

